Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2023-04-27 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Report Q1 2023' and contains comprehensive financial statements, including income statements, cash flow data, and detailed management commentary on business performance, R&D, and market outlook. It is clearly a quarterly financial report, not an announcement or a summary, as it provides substantive financial data and analysis for the specified period. Q1 2023
2023-04-27 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for Q1 2023, as indicated by the title 'Delårsrapport Kv 1 2023'. It contains comprehensive financial statements, including income statements, cash flow data, and key performance indicators (EBITDA, net sales, earnings per share) for the specified period. It also includes management commentary (VD kommentar) and operational updates. It is not an announcement of a report, but the report itself, and it contains substantive financial data, fitting the definition of an Interim/Quarterly Report. Q1 2023
2023-04-27 Swedish
Kommuniké från Orexo AB:s årsstämma
AGM Information Classification · 1% confidence The document is explicitly titled "Kommuniké från Orexo AB:s årsstämma den 18 april 2023" (Communiqué from Orexo AB's Annual General Meeting held on April 18, 2023). It details the resolutions passed at the AGM, including the election of the board, remuneration decisions, approval of financial statements, and authorizations for share issuance/repurchase. This content directly corresponds to the materials presented or summarized during an Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R). Although it mentions that full proposals are available on the website, the document itself is a summary/communiqué of the meeting's outcomes, not just an announcement of a report's availability (RPA).
2023-04-18 Swedish
Report from Orexo AB’s annual general meeting
AGM Information Classification · 1% confidence The document is explicitly titled 'Report from Orexo AB's annual general meeting, 18 April 2023'. It details resolutions passed regarding the election of the board of directors, auditor fees, approval of financial statements, dividend policy, and authorizations for share issuance/repurchase. These are all core activities and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2023-04-18 English
Orexo uppdaterar tidplanen för högdosläkemedlet vid opioidöverdos, OX124
Legal Proceedings Report Classification · 1% confidence The document is a press release dated April 3, 2023, announcing an update to the timeline for the US launch of a drug candidate (OX124) due to technical challenges in the secondary packaging process, which necessitates filing a new New Drug Application (NDA) with the FDA. This is a specific operational update concerning regulatory submissions and product development timelines, not a full financial report (like 10-K or IR), an earnings release (ER), or a general regulatory filing (RNS). It details management commentary and clinical study context related to the drug application process. Since it is an announcement regarding a regulatory submission delay and operational update, it fits best under 'Regulatory Filings' (RNS) as a general corporate announcement, although it contains elements of management commentary. However, given the content is a direct announcement of a regulatory step (filing a new NDA) and a timeline change, and it is not one of the highly specific categories like DIRS, DIV, or CAP, RNS serves as the most appropriate general regulatory announcement category for this type of news update.
2023-04-03 Swedish
Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124
Earnings Release Classification · 1% confidence The document is explicitly titled "Press release" and announces an update regarding the timeline for a drug (OX124) submission to the FDA, including delays and expected resubmission dates (Q3 2023). This type of announcement, detailing operational updates, regulatory interactions, and financial/product timelines outside of a formal quarterly/annual report structure, most closely aligns with an Earnings Release (ER) if it contained key financial highlights, or a general Regulatory Filing (RNS) if it's purely operational/regulatory news. Since it is a press release announcing a significant operational/regulatory update (NDA resubmission timeline) rather than a full financial report (10-K, IR) or a formal regulatory filing attachment, it fits best under the general announcement category. Given the options, 'ER' (Earnings Release) is often used for press releases containing material updates, even if financial figures are sparse, but 'RNS' (Regulatory Filings) serves as the best general category for material, non-standardized operational news releases that aren't explicitly defined elsewhere. However, because it is a press release detailing operational progress and regulatory feedback on a key product, and it is not a formal financial report, 'RNS' is the most appropriate fallback for material, non-financial-specific announcements. Q3 2023
2023-04-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.